Results for this period
First quarter1 April 2026–30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Net sales remained low because sales of リハート are scheduled to begin after its inclusion in the public health insurance reimbursement system. The main factors behind the losses were higher research and development expenses, reflecting increased joint research expenses with Stanford University and a decline in receipts for joint research and development expenses following the termination of the joint research and development agreement.
None (the notes on going concern state that there are no applicable matters)
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026–30 June 2026 |
| Net Sales | ¥1 million (YoY -98.2%) |
| Operating profit | ¥-333 million |
| Ordinary income | ¥-321 million |
| Profit attributable to owners of the parent | ¥-317 million |
| Net income per share | −¥38.48 |
| Equity ratio | End of the current fiscal period 91.1 / End of previous period 91.6 |
| Total assets | ¥4,811 million |
| Net assets | ¥4,457 million |
| Full-year earnings forecast | Net Sales ¥540 million (YoY +154.3%) / Operating profit ¥-1,030 million / Ordinary income ¥-580 million / Profit attributable to owners of the parent ¥-570 million |
| Annual Dividend Forecast | 0 yen and sen → 0 yen and sen |
| Depreciation and amortization | ¥32,139 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income ¥486 thousand / Extraordinary loss Not disclosed |
| Disclosure regarding the going concern assumption | None (the notes on going concern state that there are no applicable matters) |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | No (no companies newly consolidated or excluded) |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | No (instead of holding an earnings briefing, the Company plans to stream an earnings presentation video on its website) |
| Issued Shares at Period-End | 8,274,576 |
| Treasury Shares at Period-End | 15,896 |
| Factors Behind Changes in Business Performance | Net sales remained low because sales of リハート are scheduled to begin after its inclusion in the public health insurance reimbursement system. The main factors behind the losses were higher research and development expenses, reflecting increased joint research expenses with Stanford University and a decline in receipts for joint research and development expenses following the termination of the joint research and development agreement. |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Sales of リハート (a regenerative medicine product) are scheduled to begin on or after 1 September 2026, following its inclusion in the public health insurance reimbursement system. In addition, research and development expenses increased because joint research expenses with Stanford University rose, while receipts for joint research and development expenses declined from the same period of the previous year following the termination of the joint research and development agreement upon obtaining marketing approval for リハート.